|
Name |
Terretonin A
|
Molecular Formula | C26H32O8 | |
IUPAC Name* |
methyl (2R,4aS,4bR,10aR,10bR,12aR)-6-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-1,4,5,8-tetraoxo-9,10,10b,11-tetrahydro-4aH-naphtho[1,2-h]isochromene-2-carboxylate
|
|
SMILES |
C[C@]12CCC(=O)C(C1=C(C(=O)[C@@]3([C@@H]2CC(=C)[C@]4([C@H]3C(=O)O[C@@](C4=O)(C)C(=O)OC)C)C)O)(C)C
|
|
InChI |
InChI=1S/C26H32O8/c1-12-11-13-23(4)10-9-14(27)22(2,3)16(23)15(28)18(29)25(13,6)17-19(30)34-26(7,21(32)33-8)20(31)24(12,17)5/h13,17,28H,1,9-11H2,2-8H3/t13-,17-,23-,24+,25-,26-/m1/s1
|
|
InChIKey |
GTEJJXOFLPCZGJ-DOFPOEDPSA-N
|
|
Synonyms |
Terretonin A; methyl (2R,4aS,4bR,10aR,10bR,12aR)-6-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-1,4,5,8-tetraoxo-9,10,10b,11-tetrahydro-4aH-naphtho[1,2-h]isochromene-2-carboxylate; CHEMBL470042; BDBM50478873; 865092-86-0
|
|
CAS | NA | |
PubChem CID | 11547355 | |
ChEMBL ID | CHEMBL470042 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 472.5 | ALogp: | 2.2 |
HBD: | 1 | HBA: | 8 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 124.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.347 |
Caco-2 Permeability: | -5.265 | MDCK Permeability: | 0.00003370 |
Pgp-inhibitor: | 0.986 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.033 | 20% Bioavailability (F20%): | 0.752 |
30% Bioavailability (F30%): | 0.878 |
Blood-Brain-Barrier Penetration (BBB): | 0.384 | Plasma Protein Binding (PPB): | 67.31% |
Volume Distribution (VD): | 0.352 | Fu: | 34.98% |
CYP1A2-inhibitor: | 0.004 | CYP1A2-substrate: | 0.955 |
CYP2C19-inhibitor: | 0.108 | CYP2C19-substrate: | 0.878 |
CYP2C9-inhibitor: | 0.082 | CYP2C9-substrate: | 0.055 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.088 |
CYP3A4-inhibitor: | 0.834 | CYP3A4-substrate: | 0.804 |
Clearance (CL): | 3.099 | Half-life (T1/2): | 0.642 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.114 |
Drug-inuced Liver Injury (DILI): | 0.807 | AMES Toxicity: | 0.238 |
Rat Oral Acute Toxicity: | 0.061 | Maximum Recommended Daily Dose: | 0.082 |
Skin Sensitization: | 0.072 | Carcinogencity: | 0.035 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.743 |
Respiratory Toxicity: | 0.281 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005250 | 0.776 | D0H2MO | 0.236 | ||||
ENC003284 | 0.712 | D0Q4SD | 0.229 | ||||
ENC002369 | 0.712 | D0X4RS | 0.219 | ||||
ENC006004 | 0.558 | D0EP0C | 0.216 | ||||
ENC003850 | 0.552 | D0D2VS | 0.211 | ||||
ENC003376 | 0.392 | D0Y2YP | 0.211 | ||||
ENC002033 | 0.385 | D04GJN | 0.209 | ||||
ENC005629 | 0.341 | D0IX6I | 0.205 | ||||
ENC005403 | 0.325 | D06IIB | 0.203 | ||||
ENC005318 | 0.324 | D0I2SD | 0.200 |